
Long Noncoding RNA Interleukin 6 Antisense RNA 1 Promotes Inflammatory Effects in Lung Macrophages via Exosomes Through the S100A9/TLR4 Pathway in Chronic Obstructive Pulmonary Disease Progression
简介:
- 作者: Erkang Yi, Xiaoyu Wang, Yu Liu, Zihui Wang, Ge Bai, Xinyue Mei, Fan Wu, Chengshu Xie, QiYang Li, Weitao Cao, Huahua Xu, Xinyuan Liu, Jieda Cui, Haiqing Li, Ruiting Sun, Xinru Ran, Wei Hong, Zhishan Deng, Bing Li, Yumin Zhou, Pixin Ran
- 杂志: MedComm (2020)
- Doi: https://www.doi.org/10.1002/mco2.70204
- 出版日期: 2025-06-6
摘要
This study investigates the role of interleukin 6 antisense RNA 1 (IL6‐AS1), a highly expressed long noncoding RNA (lncRNA), in chronic obstructive pulmonary disease (COPD). An adeno‐associated virus (AAV) was used to induce the expression of IL6‐AS1 in mice, and they were exposed to cigarette smoke to establish a COPD model. IL6‐AS1‐overexpressing mice exposed to cigarette smoke demonstrated exacerbated COPD‐like pathologies. Integrated with single‐cell RNA sequencing analysis of COPD patients and pulmonary fibroblast–macrophage coculture system, our findings indicate that the upregulation of IL6‐AS1 in fibroblasts enhances the interaction between the S100A9 protein and the AGER and TLR4 receptors on lung macrophages, thereby exacerbating pulmonary inflammation. The molecular mechanism likely involves exosome‐mediated secretion, with IL6‐AS1 binding to S100A9 protein. These findings suggest that IL6‐AS1 may facilitate crosstalk between fibroblasts and macrophages, contributing to increased pulmonary inflammation, an effect that can be blocked by paquinimod. Mendelian randomization analysis further suggests a potential shared causal variant between IL6‐AS1 and COPD risk. Taken together, this investigation provides valuable insights into the function of IL6‐AS1 and its potential implications for the pathogenesis and therapeutic strategies in COPD.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。
